Evidence map›Paper›PMID 31344445›Full record

ArticleInternational journal of pharmaceutics2019

Determinants of preferential renal accumulation of synthetic polymers in acute kidney injury.

Yi Chen, Weimin Tang, Fei Yu, Ying Xie, Lee Jaramillo, Hee-Seong Jang, Jing Li, Babu J Padanilam, David Oupický

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. A sub-10-nm, folic acid-conjugated gold nanoparticle as self-therapeutic treatment of tubulointerstitial fibrosis.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  3. Novel Drug Delivery Technologies and Targets for Renal Disease.Hypertension (Dallas, Tex. : 1979) · 2022
    Review
  4. Article
  5. Review
  6. Preferential siRNA delivery to injured kidneys for combination treatment of acute kidney injury.Journal of controlled release : official journal of the Controlled Release Society · 2022
    Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yi ChenCenter for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Weimin TangCenter for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Fei YuCenter for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Ying XieCenter for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Lee JaramilloCenter for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Hee-Seong JangDepartment of Cellular and Integrative Physiology, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Jing LiCenter for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Babu J PadanilamDepartment of Cellular and Integrative Physiology, University of Nebraska Medical Center, Omaha, NE 68198, USA; Department of Internal Medicine, Section of Nephrology, University of Nebraska Medical Center, Omaha, NE, USA.
David OupickýCenter for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, USA. Electronic address: david.oupicky@unmc.edu.
University of Nebraska Medical Center · US

Funding

Development of siRNA conjugates for combination treatment of acute kidney injuryR01DK120533 · NIDDK · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI OUPICKY, DAVID, PADANILAM, BABU JOSEPH · 2018 to 2022
$2.1M
NIDDK NIH HHS R01 DK120533
6 · The paper itself

Abstract

Acute kidney injury (AKI) is a major kidney disease associated with high mortality and morbidity. AKI may lead to chronic kidney disease and end-stage renal disease. Currently, the management of AKI is mainly focused on supportive treatments. Previous studies showed macromolecular delivery systems as a promising method to target AKI, but little is known about how physicochemical properties affect the renal accumulation of polymers in ischemia-reperfusion AKI. In this study, a panel of fluorescently labeled polymers with a range of molecular weights and net charge was synthesized by living radical polymerization. By testing biodistribution of the polymers in unilateral ischemia-reperfusion mouse model of AKI, the results showed that negatively charged and neutral polymers had the greatest potential for selectively accumulating in I/R kidneys. The polymers passed through glomerulus and were retained in proximal tubular cells for up to 24 h after injection. The results obtained in the unilateral model were validated in a bilateral ischemic-reperfusion model. This study demonstrates for the first time that polymers with specific physicochemical characteristics exhibit promising ability to accumulate in the injured AKI kidney, providing initial insights on their use as polymeric drug delivery systems in AKI.

Indexed as

Acute Kidney InjuryAnimalsCell LineCell SurvivalKidneyMaleMice, Inbred C57BLPolymersReperfusion InjuryTissue DistributionPolymersAcute kidney injuryIschemia-reperfusionPolymersRenal delivery

Identifiers

PMID31344445
PMCPMC6708481
OpenAlexW2963597460

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.